AnteoTech (ADO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Nov, 2026Financial performance review
FY2026 sales revenue was A$467,589, versus A$968,878 in FY2025 and A$460,397 in FY2024; FY2025 included an additional SII payment of A$276,863.
A further A$134,138 SII sale completed on 7 July 2026 is being recognised in FY2027.
FY2026 expenses, excluding depreciation, amortisation and share-based payments, were A$6,857,881, versus A$8,451,114 in FY2025 and A$10,892,231 in FY2024.
Board and executive committee updates
Glenda McLoughlin serves as Non-Executive Chair, with investment banking, commercial advisory, ASX founding, energy and infrastructure experience.
Dr. Geoff Cumming serves as Non-Executive Director; his experience spans research, sales, marketing and executive roles at Roche, and he also sits on the INOVIQ Ltd board.
Merrill Gray is Managing Director and CEO, with experience in energy, batteries, hydrogen and renewables.
Corporate governance
At 4 November 2026, issued shares totaled 3,265.1 million; unlisted options totaled 233.5 million, with 7% expiring in 2026 and 65% in 2028.
The top 20 shareholders held 20% of issued shares; market capitalisation was A$52 million as at 3 November 2026.
Cash, including term deposits, totaled A$11.0 million as at 30 September 2026.
Latest events from AnteoTech
- Commercial execution advanced, with A$11.0m cash supporting the sales-conversion push.ADO
Q1 2027 TU - AnteoBind’s growth plan combines four-platform reach with supply and co-development partnerships.ADO
Investor presentation - Net loss narrowed and total revenue reached $3.13M as commercialization advanced in FY2026.ADO
H2 2026 - Ultranode™ 95 validated for drones, new products launched, and cash reserves rose to A$11.2M.ADO
Q4 2026 TU - Scaling high-silicon battery tech and diagnostics for global growth with strong market momentum.ADO
Investor presentation - Record product evaluations and global partnerships drive growth in life sciences and batteries.ADO
Investor presentation - Cash-rich, debt-free, with major product launches and global partnerships driving growth.ADO
Q3 2026 TU - Revenue up, loss down, first commercial sales and major contract secured; going concern risk flagged.ADO
H2 2024 - Proprietary chemistry and AnteoBind NXT drive diagnostics growth and global expansion.ADO
NWR Virtual Healthcare Conference